US Stock MarketDetailed Quotes
GROY Gold Royalty
- 1.500
- +0.090+6.38%
Close Oct 18 16:00 ET
- 1.480
- -0.020-1.33%
Post 20:01 ET
253.60MMarket Cap-9375P/E (TTM)
1.500High1.410Low1.71MVolume1.420Open1.410Pre Close2.53MTurnover1.34%Turnover RatioLossP/E (Static)169.07MShares2.21052wk High0.46P/B192.06MFloat Cap1.17052wk Low--Dividend TTM128.04MShs Float6.912Historical High--Div YieldTTM6.38%Amplitude1.170Historical Low1.473Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Gold Royalty Stock Forum
•Quarterly revenue of $1.8 million and Total Revenue, Land Agreement Proceeds and Interest of $2.2 million (947 GEOs), represented an approximate 300% increase compared to the same period of 2023. In the second quarter of 2024, the Company recorded its first royalty payment from IAMGOLD’s Côté Gold Mine and continued to benefit from its existing cash flowing royalties at the Borborema Proj...
● Approximate 300% increase in both revenue and Total Revenue, Land Agreement Proceeds and Interest* from the same period of 2023. ● Côté royalty, acquired in 2022, commences payments in the second quarter of 2024. Vancouver, British Columbia – July 22, 2024 – Gold Royalty Corp. (“Gold Royalty” or the “Company”) (NYSE American: GROY) is pleased to announce strong second quarter 2024 revenue and Total Reven...
Gold Royalty Completes Vares Copper Stream Acquisition
Gold Royalty Announces US$30 Million Bought Deal Financing
NEWS
GOLD ROYALTY ANNOUNCES RECORD TOTAL REVENUE, LAND AGREEMENT PROCEEDS AND INTEREST AND GEOS
Gold Royalty Corp. announces record total revenue, land agreement proceeds, and interest in the first quarter of 2024, driven by cornerstone royalties and recent acquisitions. The company recorded $4.2 million in total revenue, with a 112% increase from the previous year, and is on track to meet its forecasted 2024 revenue of $10.0 to 11.2 million. The company's unique royalty ...
here because of charlie!
In reaction to earnings/guidance:
• $Thor Industries (THO.US)$ +2.5%
Other news:
• $Acumen Pharmaceuticals (ABOS.US)$+76.8% (in response with BIIB)
• $Biogen (BIIB.US)$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging (NNOX.US)$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen (OCGN.US)$ +9.3% (en...
• $Actinium (ATNM.US)$ +30.81% (Actinum Pharma and Immedica to commercialize lomab-B (1311 apamistamab) in Europe the Middle East and North Africa)
• $Aeglea BioTherapeutics (AGLE.US)$ +18.11% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
• $Grid Dynamics (GDYN.US)$ +5% (expands in Europe ceases operations in Russia)
• $Artisan Partners Asset Management (APAM.US)$ +4....
No comment yet